logo
Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Perspective Therapeutics Commences Recruitment for [212Pb]VMT-α-NET in the Third Dose Escalation Cohort of its Ongoing Phase 1/2a Clinical Trial

Yahoo21-06-2025
[212Pb]VMT-α-NET Phase 1/2a study is advancing into Cohort 3 with a fixed administered dose that is up to 20% higher (6 mCi) than the dose administered to patients in Cohort 2
Dosimetry sub-study analysis presented at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2025 Annual Meeting to advance utility of dosimetry in clinical development when considered with clinical data
On track to submit further clinical updates to scientific congresses in 2H 2025, including longer safety follow-up on all patients who have received at least one treatment of [212Pb]VMT-α-NET and anti-tumor activities in patients dosed to date who have had the opportunity to receive at least one scan after their full treatment
SEATTLE, June 21, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced that alignment was reached with the U.S. Food and Drug Administration (FDA) to open the third dosing cohort (Cohort 3) of its ongoing Phase 1/2a clinical trial for [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor 2 (SSTR2)-positive neuroendocrine tumors (NETs) who have not received prior radiopharmaceutical therapies (RPT).
"We are excited to start exploring a higher dose level of VMT-α-NET after successfully completing an interaction with the FDA that was agreed prior to commencement of this trial," commented Markus Puhlmann, Chief Medical Officer of Perspective. "We are encouraged by the overall clinical profile observed at the second dose level of VMT-α-NET—including evidence of anti-tumor activity and primarily low-grade adverse events—and we believe it is important to assess whether a higher dose could further improve the therapeutic profile. Meanwhile, we remain committed to engaging with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of our proprietary RPTs."
Patients in Cohort 3 will receive up to four fixed administered doses of [212Pb]VMT-α-NET at 6 mCi every eight weeks if they weigh more than 60kg (133lb), or 100μCi/kg of body weight if they weigh less than or equal to 60kg. Observations of dose limiting toxicities (DLTs) in up to eight patients within 42 days of the first treatment cycle will be used to assess whether this cohort of patients have received maximum tolerated dose (MTD) or maximum feasible dose (MFD). Once a safety monitoring committee (SMC) has reviewed the data from these initial patients, it may recommend exploring alternative dosing and/or recruit more patients into Cohort 3.
Perspective is notifying sites that Cohort 3 is now open for recruitment. Patients currently being evaluated for entry into the study will enroll into Cohort 3 if they qualify. Pending feedback from sites on operationalizing enrollment into Cohort 3, an update on pace of recruitment will be provided in due course.
About [212Pb]VMT-α-NETPerspective designed [212Pb]VMT-α-NET to target and deliver 212Pb to tumor sites expressing SSTR2. The Company is conducting a multi-center, open-label, dose-escalation, dose-expansion study (clinicaltrials.gov identifier NCT05636618) of [212Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive neuroendocrine tumors who have not received a prior RPT. Interim update with a data cut-off date of April 30, 2025 were reported in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2025. Cohort 2 was reopened in August 2024. During 2H 2025, some of the 33 additional patients enrolled after the cohort reopened and through April 30, 2025 will have had the opportunity for at least 32 weeks of follow-up after their initial doses, sufficient time to receive at least one scan after their full treatment (up to four doses every eight weeks), if they receive all four doses of treatment per protocol.
About Perspective Therapeutics, Inc.Perspective Therapeutics, Inc. is a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.
The Company's melanoma (VMT01), neuroendocrine tumor (VMT-α-NET), and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S. The Company is growing its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations.
For more information, please visit the Company's website at www.perspectivetherapeutics.com.
Safe Harbor StatementThis press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatments for cancers throughout the body; the Company's belief that it is on track to submit further clinical updates to scientific congresses in 2H 2025 and the planned content of such updates; the Company's ability to explore a higher dose level of VMT-α-NET; the Company's commitment to engage with the FDA to evaluate the clinical utility of dosimetry estimates and analyses in the development of its proprietary RPTs; the Company's expectation that patients currently being evaluated for entry into its VMT-α-NET study will enroll into Cohort 3 if they qualify; the ability of the Company's proprietary technology utilizing the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties; the Company's prediction that the use of complementary imaging diagnostics that incorporate the same targeting moieties provides the opportunity to personalize treatment and optimize patient outcomes; the Company's belief that its "theranostic" approach enables the ability to see a specific tumor and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to grow its regional network of drug product finishing facilities, enabled by its proprietary 212Pb generator, to deliver patient-ready products for clinical trials and commercial operations; and other statements that are not historical fact.
These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media and Investor Relations Contacts:
Perspective Therapeutics IR:Annie J. Cheng, CFAir@perspectivetherapeutics.com
Russo Partners, LLCNic JohnsonPerspectiveIR@russopr.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

From balance sheet to alpha engine: The Bitcoin treasury strategy arms race
From balance sheet to alpha engine: The Bitcoin treasury strategy arms race

Yahoo

time25 minutes ago

  • Yahoo

From balance sheet to alpha engine: The Bitcoin treasury strategy arms race

From balance sheet to alpha engine: The Bitcoin treasury strategy arms race originally appeared on TheStreet. Bitcoin treasuries have moved from a curiosity to a capital markets trend with teeth. What began as MicroStrategy's audacious balance sheet bet has ballooned into a $100 billion movement across public and private companies. The question now isn't whether to hold Bitcoin—it's how to manage it. Today's treasuries are increasingly being scrutinized not just for exposure, but for strategy. Passive buy-and-hold approaches—common among early adopters—are now being challenged by firms looking to generate yield, hedge volatility, and even deploy AI-driven trading overlays. 'Everyone wants to have this Bitcoin treasury so that people can get proxy exposure to Bitcoin,' said David Brickell of FRNT. 'But it kind of seems a waste of balance sheet. How do we actually maximize that?' The answer, for many, lies in treating Bitcoin less like gold and more like a yield-generating portfolio asset. Firms like FRNT and Hilbert Capital are experimenting with frameworks borrowed from traditional corporate treasury practices: optimizing for drawdowns, layering in risk management tools, and targeting alpha without compromising core holdings. This approach aims to deliver returns that outperform Bitcoin itself—without exposing the firm to catastrophic downside. But as more companies jump in, the space is becoming noisy. 'When people like GameStop are doing it, borrowing money to buy Bitcoin, it starts to feel bubbly,' said Lucy Balicki. The market has begun to blur the line between strategic treasury allocation and stock-pumping theatrics. Still, the trend is clear: Bitcoin is no longer just a speculative asset. It's becoming a programmable layer of corporate finance. And in this new era, the winners won't just be the ones who hold the most BTC—they'll be the ones who manage it best. From balance sheet to alpha engine: The Bitcoin treasury strategy arms race first appeared on TheStreet on Jul 23, 2025 This story was originally reported by TheStreet on Jul 23, 2025, where it first appeared. Sign in to access your portfolio

Alphabet (GOOGL) Gets $190 Price Target Ahead of Earnings, Analyst Sees Favorable Setup
Alphabet (GOOGL) Gets $190 Price Target Ahead of Earnings, Analyst Sees Favorable Setup

Yahoo

time25 minutes ago

  • Yahoo

Alphabet (GOOGL) Gets $190 Price Target Ahead of Earnings, Analyst Sees Favorable Setup

Alphabet Inc. (NASDAQ:) is one of the . On July 21, Wolfe Research analyst Shweta Khajuria reiterated an 'Outperform' rating on the stock with a $190.00 price target. The rating affirmation comes ahead of Alphabet's second-quarter earnings report scheduled for Tuesday, July 22nd. The firm noted that even though it's going to 'skew long into the print,' there may not be enough investor focus as it would be diverted to the upcoming Search ruling anticipated in August. The firm highlighted how Alphabet shares have outperformed the S&P 500 by 1 percentage point since the last earnings release, driven by a 'friendly setup,' improving advertising environment, and its AI narrative for Gemini models. Photo by on Unsplash Wolfe Research noted that it will be all ears for Alphabet's updates on the AI mode and AI overview monetization during the earnings call. Any metric disclosures may move beyond clicks growth and come during Q3 call or later. Alphabet Inc. (NASDAQ:GOOGL) is an American multinational technology conglomerate holding company wholly owning the internet giant Google, amongst other businesses. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Sign in to access your portfolio

HR Exec Who Was Seen Wrapped in CEO's Arms in Viral Coldplay Video Remains in Role as Company Moves Forward
HR Exec Who Was Seen Wrapped in CEO's Arms in Viral Coldplay Video Remains in Role as Company Moves Forward

Yahoo

time25 minutes ago

  • Yahoo

HR Exec Who Was Seen Wrapped in CEO's Arms in Viral Coldplay Video Remains in Role as Company Moves Forward

While Astronomer CEO Andy Byron resigned over the weekend after he was seen wrapping his arms around one of his female executives at a concert, she appears to still be with the company as new leadership is vowing to move forward. Kristin Cabot, Astronomer's chief people officer, was caught in the now-infamous clip with Byron in the audience at a Coldplay show in Massachusetts last week. Their unusual reaction — she quickly turned her back to the so-called "kiss cam" and he ducked out of sight — led Martin to joke that 'either they're having an affair or they're just very shy.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer​​, from celebrity news to compelling human interest stories. Both Byron and Cabot are reportedly married; neither has spoken publicly about the nature of their relationship. As of Wednesday, July 23, Cabot is still listed on the company website in her role as chief people officer, though Byron has been removed. (Efforts to reach her for comment have been unsuccessful.) An Astronomer spokesman previously said that "no other employees were in the video." The entire imbroglio spawned countless memes and mockery and put a national spotlight, for a few days, on the former colleagues. Many online purported to dig up and share personal details about both of their families. The controversy was also the subject of much discussion about the nature of privacy in a digital age and what behavior should and shouldn't subject someone to public scrutiny. In a press release in November announcing Cabot's hiring at Astronomer, Byron was quoted as saying her 'exceptional leadership and deep expertise in talent management, employee engagement, and scaling people strategies will be critical as we continue our rapid trajectory. She is a proven leader.' In a statement after Byron stepped down titled "Moving Forward at Astronomer," his replacement, Pete DeJoy, acknowledged that 'the events of the past few days have received a level of media attention that few companies—let alone startups in our small corner of the data and AI world—ever encounter." All of the attention had been 'unusual and surreal for our team,' DeJoy said, 'and, while I would never have wished for it to happen like this, Astronomer is now a household name." Read the original article on People

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store